Showing 341-350 of 5834 results for "".
From PA to Medical Director: An Interview with Kim Sanders, PA-C
https://practicaldermatology.com/topics/pas-nps/making-your-way-derm-pa-interview-kim-sanders-pa-c/26918/From PA to Medical Director: An Interview with Kim Sanders, PA-COpen Payments Program: Does it Enhance Open Discussion About Financial Ties Between Dermatologists and Industry?
https://practicaldermatology.com/youngmd-connect/resident-resource-center/open-payments-program-does-it-enhance-open-discussion-about-financial-ties-between-dermatologists-and-industry/23619/The majority of physicians practicing in the United States have received some form of compensation from private industry during their careers. These payments may include consulting fees, compensation for speaking engagements, and stock options. Certain payments take indirect forms, such as physicJanssen Approvals, New Thermage FLX, Restylane Silk Cannulas
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-janssen-approvals-new-thermage-flx-restylane-silk-cannulas/18401/Janssen Biotech's Stelara is now approved for the treatment of adolescents 12 years of age or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Janssen's SIMPONI ARIA® cleared for the treatment of adults with active psoriatic arthritis or activeScience of Skincare Summit 2024: On the FDA Approval of Emrosi for Rosacea
https://practicaldermatology.com/conferences/science-skincare-summit-2024/science-of-skincare-summit-2024-on-the-fda-approval-of-emrosi-for-rosacea/29276/At the Science of Skincare Summit in Austin, Practical Dermatology caught up with Chief Medical Editor Neal Bhatia, MD, and James Del Rosso, DO, a dermatologist and Editor in Chief of Clinical Dermatology at the Journal of Clinical and Aesthetic Dermatology (JCAD), who shared insights and thoughts oSeborrheic Dermatitis Update: A Review of the Etiology and Treatment of Seborrheic Dermatitis
https://practicaldermatology.com/topics/other-dermatitis/seborrheic-dermatitis-update-a-review-of-the-etiology-and-treatment-of-seborrheic-dermatitis/24003/Seborrheic dermatitis (SD) is an inflammatory skin condition that often involves flaky, erythematous patches on sebum-rich areas of the body such as the face and scalp.1 At least 50 million Americans have a form of seborrheic dermatitis on the scalp, more commonly known as dandruff. SD presents in aFour Gen Z trends that dermatology practices should know
https://practicaldermatology.com/topics/practice-management/four-gen-z-trends-that-dermatology-practices-should-know/20007/As Generation Z continues to mature, their behaviors as consumers will increasingly guide how practices and other organizations appeal to them. Why not get a jumpstart? At Ekwa Marketing, we got into the heads of a generation that is increasingly exerting its influence on household buying decisionsFive ways to promote new treatments
https://practicaldermatology.com/topics/practice-management/five-ways-to-promote-new-treatments/20001/The dermatology device market is booming. It takes particular skills to distinguish between those innovative technologies that provide a great value to your patients and those that are less about substance and more about sexy marketing. Likewise, your current patients and “lurkers” on your social meDermWireTV: COVID-19 Loans, Taltz for Peds, Finacea Returns
https://practicaldermatology.com/topics/practice-management/dermwiretv-covid-19-loans-taltz-for-peds-finacea-returns/19808/SBA Loans and Paycheck Protection Program (PPP) loans for practices impacted by the coronavirus pandemic are among the options addressed in a new video series, “Coping with COVID-19.” Eli Lilly and Company's Taltz is now approved to manage moderate to severe plaque psoriasis in pediatric patients aAllergan Commemorates 25th Anniversary of the First Two Approved Uses of BOTOX® (onabotulinumtoxinA)
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/allergan-commemorates-25th-anniversary-of-the-first-two-approved-uses-of-botox-onabotulinumtoxina-/19136/Allergan, Inc. (NYSE: AGN) today announced the launch of a video recognizing the physician pioneers and patient communities who contributed to the development of BOTOX® (onabotulinumtoxinA), one of the most recognized pharmaceutical brands in the United States. The video kicks off a year-long campaiDermWire TV Extra: Dr. Ruiz on GEP Testing for SCC
https://practicaldermatology.com/topics/skin-of-color/dermwire-tv-extra-dr-ruiz-gep-testing-scc/29497/Emily Ruiz, MD, MPH, FAAD, a Mohs surgeon at Brigham and Women's Hospital and cutaneous oncologist at Dana-Farber Cancer Institute, discusses her recent Future Oncology article, "Predicting adjuvant radiation therapy benefit in cutaneous squamous cell carcinoma with the 40-gene expression profile."